The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.
"Advance the comprehensive management of allergy and inflammatory disease in Otolaryngology-Head and Neck Surgery through training, education, and advocacy."
As part of our on-going member support, we are introducing a new website feature to help with common practice management challenges. We welcome your input with questions or challenges you would like to address. Read More
FDA has a drug shortage database which includes reasons for and updates on drug shortages. Today the…
An updated draft of USP Chapter 797 was released today. Updated Chapter 797 Posted for Public Comment: Separate Requirements…
The second year of the Quality Payment Program (QPP) authorized by the Medicare Access and…
12/01/24: Research Grant Cycle
Learn more
04/01/25: Fellow Exam Application Deadline
Learn more
06/01/25: Research Grant Cycle
Learn more
08/08/25: Scientific Abstract Submission Deadline
Learn more
Thanks to your feedback, we have reimagined our Advanced Course in Allergy & Immunology to give you educational programming that encompasses your full scope of practice. Join us for the new Explorers Course 2025: Surgical & Medical Management of Airway Disease in Otolaryngology. Learn More
We are pleased to invite you to participate in the 2025 AAOA Annual Meeting Call for Proposals. Do you have burning content ideas to be presented at the Annual Meeting? The AAOA is seeking proposals to incorporate in the educational sessions for the 2025 Annual Meeting. Learn More
For information about Resident membership, opportunities, DosedDaily, research grants, and other resources. Learn More
IFAR Impact Factor: 2.454
IFAR Featured Content: COVID-19 - Free Access
Endonasal instrumentation and aerosolization risk in the era of COVID‐19: simulation, literature review, and proposed mitigation strategies . Read More
Explorers Course 2025:
Surgical & Medical Management of Airway Disease in Otolaryngology — Hybrid
90-days Access Feb 27 – May 30, 2025
March 27-29, 2025 - Live
The Hythe, Vail, CO
Learn More and Register
2025 AAOA Basic Course in Allergy & Immunology - Hybrid
90-days Access June 10 – Sep 15, 2025
July 10-12, 2025 - Live
The Chateaux Deer Valley, Park City, UT
Learn More and Register
USP 797 Online Module
Learn More and Register
AAOA Educational Stacks
Available Now!
July 2021 marks an almost 18 month journey through COVID. We have witnessed and personally…
As the challenges of the pandemic change, Project N95 continues to evolve to meet community…
Those interested can still register and stream a video of the webcast at the link…
The American Academy of Otolaryngic Allergy (AAOA) Practice Resource Tool Kit is intended as a guide to help AAOA members integrate allergy into their otolaryngology practice and to continually improve on this integration as new information, regulations, and resources become available.
AAOA has launched a Partner Resource Center to bring you partner resources that can assist your practice and patient care.
The Food and Drug Administration (FDA) has approved ProAir Digihaler (albuterol sulfate) inhalation powder for the treatment or prevention of bronchospasm in patients aged 4 years and older with reversable obstructive airway disease, and for prevention of exercise-induced bronchospasm (EIB)…
...the AAOA continues to be the organization that Otolaryngologists look to for up-to-date education and information on the practice of Allergy. I attended my first AAOA Course 20 years ago and have witnessed significant changes in how we diagnose and treat allergic disease. Older diagnostic and…
I want to urge you to consider membership in the AMA because your membership in AMA gives us a voice. The American Medical Association is one organization that the AAOA works through to advocate for issues related to the AAOA. …
Revisions to USP Chapter 797 Open for Comment Since the United States Pharmacopeia (USP) released a proposed update to Chapter 797 in 2015, AAOA has been working with other concerned organizations including the American Academy of Allergy, Asthma & Immunology,…
On November 1, the Centers for Medicare and Medicaid Services released the final Physician Fee Schedule (PFS) detailing policies related to Medicare physician payment and the Quality Payment Program (QPP). A brief summary of key provisions for AAOA members follows:…
You have allergy symptoms, and want to find something to treat your symptoms without having to go to a doctor. The allergy aisle in the pharmacy or big box store is overwhelming. What do all these drugs do? Let's break…
The Food and Drug Administration (FDA) states, in a revised draft guidance released this week, that it does not intend to enforce the “insanitary conditions” provision of the Food, Drug and Cosmetic Act against physicians that compound or mix in their…
The Advocacy Council of the American College of Allergy, Asthma and Immunology (ACAAI) together with its sponsoring organization, the ACAAI, the American Academy of Allergy, Asthma and Immunology (AAAAI), and the American Academy of Otolaryngic Allergy (AAOA) submitted comments on the proposed changes…
FDA has a drug shortage database which includes reasons for and updates on drug shortages. Today the database read, “Meridian Medical Technologies, a subsidiary of Pfizer that manufactures EpiPen® and the authorized generic version, continues to experience manufacturing constraints. Currently, supplies will vary from…
The Food and Drug Administration approves the first generic version of EpiPen and EpiPen Jr. FDA Commissioner Scott Gottlieb, M.D states that “This approval means patients living with severe allergies who require constant access to life-saving epinephrine should have a…